Hadassah

Hadassah’s Multiple Sclerosis Center: A Global Leader in Treating MS with Stem Cells

Monday, Nov 14 2011

Since 1990, the Multiple Sclerosis (MS) Center at the Hadassah University Medical Center has been conducting groundbreaking research into the use of bone marrow-derived stem cells to treat MS. Today, Hadassah’s MS Center, headed by Prof. Dimitrios Karussis, is a world leader in treating MS with stem cells.

Hadassah was the first to introduce the concept of transplanting hematopoietic cells (cells isolated from the blood or bone marrow) into MS animal models and, subsequently, MS patients. Hematopoietic cells can renew themselves and differentiate into a variety of specialized cells.

In the early 2000's, Hadassah began to focus its research efforts specifically on Bone Mesenchymal Stem cells (BMSCs) and has been conducting BMSC clinical trials since 2007, with more than 50 MS patients. The use of BMSCs may provide an alternative solution to existing treatment efforts, which are only partially effective, especially in the faster, more progressive phases of the disease.

In the world's first Phase I clinical trial to evaluate the feasibility and safety of a combined intrathecal and intravenous administration of autologous BMSCs in patients with severe MS and Amyotrophic Lateral Sclerosis (ALS), Hadassah's researchers found that the transplantation of BMSCs in patients with MS and ALS "is a clinically feasible and relatively safe procedure." Further, they explained, this transplantation "induces immediate immunomodulatory effects and some beneficial clinical effects." The clinical trial also revealed that stem cells injected intrathecally (directly into the circulating fluid of the brain and spinal cord), have a greater chance of reaching the affected areas in the central nervous system.

The Hadassah researchers note that the multiple mechanisms by which stem cells induce their beneficial effects (collectively termed "therapeutic plasticity") make them excellent candidates for developing treatments for MS patients. The ability to modulate the central nervous system's autoimmune response; to protect it from further injury; to induce endogenous repair mechanisms; and to participate accurately in remyelination (re-generation of the nerve's myelin sheath which is essential for the proper functioning of the nervous system), provides the rationale to further develop these cell therapies for MS.

The use of BMS cells. specifically, has a variety of advantages, including:

  • BMSCs are easily and safely obtained from adult bone marrow, even from patients with advanced disease
  • BMSCs that are normally present in small concentrations in bone marrow can be enriched and expanded into large numbers by in vitro culturing for therapeutic purposes
  • Autologous BMSCs are safely administered without the need for immunosuppressive treatment to prevent rejection and
  • Adult BMSCs are less prone to genetic abnormalities and malignant transformation during multiple passages in vitro, thus indicating a low risk for inducing treatment-related malignancies.

Next Step: Phase II of Hadassah's clinical trial will compare the efficacy of single versus multiple injections and the efficacy of intravenous versus intrathecal injections. This will pave the way to formulate the optimal protocol for a large-scale, multi-institutional trial.

Comments

From: Joyce on October 19, 2015
I would like to know if Hadassah is performing any studies for MS in the United States. If so, please let me have any and all information. Thank you.
From: david on October 1, 2015
October 1 2015 Sir or Mdm: I received a friendly email from Dr. Karussis, discussing the ongoing 2b efficacy trial for intrathecal stem cell transplantation. I responded to his email addresses -- dimitriosk@ekmd.huji.ac.il dimitrios@hadassah.org.il -- but until now have not heard back from him.. I would be grateful if you would kindly inform him of my interest in this program..sincerely, David Aikman
From: Frances on September 8, 2015
I would love to receive additional information regard MS treatment.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Feb 22 2017

Hadassah Medical Organization Performs Israel’s First Spina Bifida Fetal Surgery To Lessen Crippling Spinal Damage

History was made at Hadassah Ein Kerem Hospital in Jerusalem on Thursday, February 9 when a team of Israeli surgeons successfully operated on a 5-month-old fetus using a new procedure that only three doctors in the world can perform, to alleviate some of the crippling effects of Spina Bifida.

READ MORE ›
alt_text

Tuesday, Feb 21 2017

Hadassah Cardiologists Publicize Israel’s Dramatic Decrease in Cardiovascular Death

Prof. Emeritus Mervyn Gotsman and Prof. Israel Gotsman of Hadassah Hospital’s Heart Institute have coauthored an article which appeared in the European Heart Journal, highlighting the fact that “between 1998 and 2012, mortality from cardiovascular disease in Israel has fallen from 162 to 80 per 100,000 residents--a decrease of 50 percent.”

READ MORE ›
alt_text

Tuesday, Feb 21 2017

Ambassadors of Health for Heart Smart Living: A Unique Hadassah Program

Knowing that the workplace is where people spend vast quantities of time, the Hadassah Medical Organization’s Linda Joy Pollin Cardiovascular Wellness Center for Women launched a unique course to encourage heart healthy living—during the work day.

READ MORE ›
alt_text

Tuesday, Feb 21 2017

Hadassah Brings Health Empowerment to East Jerusalem

The increased incidence of diabetes in the Arab community, as well as the 60 percent higher rate of cardiovascular mortality among Arab women led the Hadassah Medical Organization’s Linda Joy Pollin Cardiovascular Wellness Center for Women to develop a community-based program to cultivate leadership that embraces and advocates for healthy living which will reduce diabetes in this population.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More